Dermatology · Charlotte, NC
NPI
1326081142
Since 2006
Specialty
Dermatology
Code 207N00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
15830 Ballantyne Medical Pl, Suite 100
Charlotte, NC, 28277
Phone (704) 341-0090
Groups this clinician bills Medicare through
Medicare paid, 2024
$151K
4,195 services
Medicare patients, 2024
884
Average age 76
Drug cost, 2024
$548K
918 prescriptions
Company payments, 2025
$683
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by James L Seward was code 17003 (destruction skin lesion), 1,812 times for 271 patients. In total James L Seward billed 4,195 services in 52 codes, and Medicare paid $151K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-10-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 1,812 | 271 | $4.32 | $7,831 |
| 99213 Office E&M - Established | Office | 1,010 | 745 | $55.21 | $56K |
| 17000 Destruction Skin Lesion | Office | 442 | 333 | $36.39 | $16K |
| 17110 Destruction Skin Lesion | Office | 202 | 185 | $73.11 | $15K |
| 11102 Skin Biopsy | Office | 184 | 150 | $60.84 | $11K |
| 99214 Office E&M - Established | Office | 89 | 73 | $75.50 | $6,719 |
| 99212 Office E&M - Established | Office | 51 | 49 | $33.37 | $1,702 |
| 17004 Destruction Skin Lesion | Office | 49 | 38 | $98.86 | $4,844 |
| 17262 Destruction Skin Lesion | Office | 43 | 33 | $107.00 | $4,601 |
| 11103 Skin Biopsy | Office | 33 | 22 | $35.57 | $1,174 |
| 12032 Wound Repair - All Levels | Office | 30 | 28 | $218.58 | $6,557 |
| 99203 Office E&M - New | Office | 26 | 26 | $58.91 | $1,532 |
| 11602 Skin Lesion Excision | Office | 21 | 19 | $90.08 | $1,892 |
| 17261 Destruction Skin Lesion | Office | 17 | 14 | $89.27 | $1,518 |
By year: 2022 $182K for 5,217 services; 2023 $177K for 4,929 services; 2024 $151K for 4,195 services.
Medicare prescription drug claims, 2024
In 2024, the drug James L Seward prescribed most often to Medicare patients was Triamcinolone Acetonide, with 71 prescriptions and refills. In total James L Seward wrote 918 Medicare prescriptions that cost $548K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Triamcinolone Acetonide Generic | 71 | 86 | 41 | $1,116 |
| Fluticasone Propionate Generic | 59 | 59 | 48 | $1,330 |
| Ketoconazole Generic | 58 | 58 | 31 | $613 |
| Hydrocortisone Generic | 56 | 56 | 40 | $195 |
| Ampicillin Trihydrate Generic | 51 | 59 | 12 | $1,574 |
| Ammonium Lactate Generic | 45 | 50 | 30 | $562 |
| Minocycline Hcl Generic | 41 | 41 | 19 | $696 |
| Alclometasone Dipropionate Generic | 41 | 42 | 25 | $1,632 |
| Methotrexate Methotrexate Sodium | 40 | 60 | Under 11 | $426 |
| Clobetasol Propionate Generic | 40 | 40 | 26 | $1,669 |
| Fluocinonide Generic | 35 | 36 | 20 | $1,554 |
| Doxycycline Hyclate Generic | 33 | 45 | 11 | $591 |
| Metronidazole Generic | 27 | 29 | 18 | $2,278 |
| Cephalexin Generic | 22 | 22 | 18 | $213 |
| Prednisone Generic | 21 | 21 | 12 | $40.89 |
Brand drugs: 81 claims; generic drugs: 837 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid James L Seward $683 ($683 in general payments such as food, travel and fees) from 10 companies. The largest payer was Janssen Biotech, Inc. with $167.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 4 | $167 |
| Genzyme Corporation SNY | 4 | $114 |
| Regeneron Healthcare Solutions, Inc. REGN | 3 | $95.36 |
| Abbvie Inc. ABBV | 4 | $92.39 |
| UCB, Inc. UCB.BR | 2 | $60.16 |
| Novartis Pharmaceuticals Corporation NVS | 2 | $50.98 |
| Pfizer Inc. PFE | 2 | $42.1 |
| Botanix SB Inc | 1 | $23.48 |
| E.R. Squibb & Sons, L.L.C. BMY | 1 | $22.04 |
| Arcutis Biotherapeutics, Inc. ARQT | 1 | $15.71 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.